vs
ICU MEDICAL INC（ICUI）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Penumbra Inc的1.4倍（$540.7M vs $385.4M）。Penumbra Inc净利率更高（12.3% vs -2.9%，领先15.2%）。Penumbra Inc同比增速更快（22.1% vs -14.1%）。Penumbra Inc自由现金流更多（$68.0M vs $36.0M）。过去两年Penumbra Inc的营收复合增速更高（17.6% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
ICUI vs PEN — 直观对比
营收规模更大
ICUI
是对方的1.4倍
$385.4M
营收增速更快
PEN
高出36.3%
-14.1%
净利率更高
PEN
高出15.2%
-2.9%
自由现金流更多
PEN
多$32.1M
$36.0M
两年增速更快
PEN
近两年复合增速
-2.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $385.4M |
| 净利润 | $-15.7M | $47.3M |
| 毛利率 | 37.5% | 68.0% |
| 营业利润率 | 1.0% | 15.4% |
| 净利率 | -2.9% | 12.3% |
| 营收同比 | -14.1% | 22.1% |
| 净利润同比 | 34.0% | 40.6% |
| 每股收益（稀释后） | $-0.63 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIPEN
| Q4 25 | $540.7M | $385.4M | ||
| Q3 25 | $537.0M | $354.7M | ||
| Q2 25 | $548.9M | $339.5M | ||
| Q1 25 | $604.7M | $324.1M | ||
| Q4 24 | $629.8M | $315.5M | ||
| Q3 24 | $589.1M | $301.0M | ||
| Q2 24 | $596.5M | $299.4M | ||
| Q1 24 | $566.7M | $278.7M |
净利润ICUIPEN
| Q4 25 | $-15.7M | $47.3M | ||
| Q3 25 | $-3.4M | $45.9M | ||
| Q2 25 | $35.3M | $45.3M | ||
| Q1 25 | $-15.5M | $39.2M | ||
| Q4 24 | $-23.8M | $33.7M | ||
| Q3 24 | $-33.0M | $29.5M | ||
| Q2 24 | $-21.4M | $-60.2M | ||
| Q1 24 | $-39.5M | $11.0M |
毛利率ICUIPEN
| Q4 25 | 37.5% | 68.0% | ||
| Q3 25 | 37.4% | 67.8% | ||
| Q2 25 | 37.9% | 66.0% | ||
| Q1 25 | 34.7% | 66.6% | ||
| Q4 24 | 36.1% | 66.8% | ||
| Q3 24 | 34.8% | 66.5% | ||
| Q2 24 | 34.8% | 54.4% | ||
| Q1 24 | 32.7% | 65.0% |
营业利润率ICUIPEN
| Q4 25 | 1.0% | 15.4% | ||
| Q3 25 | 2.6% | 13.8% | ||
| Q2 25 | 1.9% | 12.0% | ||
| Q1 25 | 2.1% | 12.4% | ||
| Q4 24 | 6.0% | 13.6% | ||
| Q3 24 | 1.4% | 11.7% | ||
| Q2 24 | 1.3% | -27.0% | ||
| Q1 24 | -1.9% | 4.3% |
净利率ICUIPEN
| Q4 25 | -2.9% | 12.3% | ||
| Q3 25 | -0.6% | 12.9% | ||
| Q2 25 | 6.4% | 13.3% | ||
| Q1 25 | -2.6% | 12.1% | ||
| Q4 24 | -3.8% | 10.7% | ||
| Q3 24 | -5.6% | 9.8% | ||
| Q2 24 | -3.6% | -20.1% | ||
| Q1 24 | -7.0% | 3.9% |
每股收益（稀释后）ICUIPEN
| Q4 25 | $-0.63 | $1.20 | ||
| Q3 25 | $-0.14 | $1.17 | ||
| Q2 25 | $1.43 | $1.15 | ||
| Q1 25 | $-0.63 | $1.00 | ||
| Q4 24 | $-0.97 | $0.88 | ||
| Q3 24 | $-1.35 | $0.75 | ||
| Q2 24 | $-0.88 | $-1.55 | ||
| Q1 24 | $-1.63 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $186.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $1.4B |
| 总资产 | $4.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIPEN
| Q4 25 | — | $186.9M | ||
| Q3 25 | — | $321.0M | ||
| Q2 25 | — | $421.8M | ||
| Q1 25 | — | $376.1M | ||
| Q4 24 | $308.6M | $324.4M | ||
| Q3 24 | $312.5M | $280.5M | ||
| Q2 24 | $302.6M | $288.3M | ||
| Q1 24 | $251.4M | $223.1M |
股东权益ICUIPEN
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.0B | $1.2B | ||
| Q4 24 | $2.0B | $1.2B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $2.0B | $1.2B | ||
| Q1 24 | $2.1B | $1.2B |
总资产ICUIPEN
| Q4 25 | $4.1B | $1.8B | ||
| Q3 25 | $4.1B | $1.7B | ||
| Q2 25 | $4.1B | $1.7B | ||
| Q1 25 | $4.2B | $1.6B | ||
| Q4 24 | $4.2B | $1.5B | ||
| Q3 24 | $4.3B | $1.5B | ||
| Q2 24 | $4.3B | $1.5B | ||
| Q1 24 | $4.3B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $68.0M |
| 自由现金流率自由现金流/营收 | 6.6% | 17.7% |
| 资本支出强度资本支出/营收 | 4.6% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.83× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $174.9M |
8季度趋势，按日历期对齐
经营现金流ICUIPEN
| Q4 25 | $60.6M | $86.5M | ||
| Q3 25 | $56.7M | $58.3M | ||
| Q2 25 | $11.2M | $44.9M | ||
| Q1 25 | $51.3M | $49.0M | ||
| Q4 24 | $40.2M | $51.1M | ||
| Q3 24 | $36.1M | $56.5M | ||
| Q2 24 | $82.0M | $22.6M | ||
| Q1 24 | $45.8M | $38.3M |
自由现金流ICUIPEN
| Q4 25 | $36.0M | $68.0M | ||
| Q3 25 | $27.6M | $42.0M | ||
| Q2 25 | $-8.5M | $29.4M | ||
| Q1 25 | $36.7M | $35.5M | ||
| Q4 24 | $16.1M | $45.7M | ||
| Q3 24 | $16.2M | $51.0M | ||
| Q2 24 | $62.5M | $18.1M | ||
| Q1 24 | $29.9M | $32.5M |
自由现金流率ICUIPEN
| Q4 25 | 6.6% | 17.7% | ||
| Q3 25 | 5.1% | 11.8% | ||
| Q2 25 | -1.5% | 8.7% | ||
| Q1 25 | 6.1% | 11.0% | ||
| Q4 24 | 2.6% | 14.5% | ||
| Q3 24 | 2.7% | 16.9% | ||
| Q2 24 | 10.5% | 6.0% | ||
| Q1 24 | 5.3% | 11.7% |
资本支出强度ICUIPEN
| Q4 25 | 4.6% | 4.8% | ||
| Q3 25 | 5.4% | 4.6% | ||
| Q2 25 | 3.6% | 4.6% | ||
| Q1 25 | 2.4% | 4.2% | ||
| Q4 24 | 3.8% | 1.7% | ||
| Q3 24 | 3.4% | 1.8% | ||
| Q2 24 | 3.3% | 1.5% | ||
| Q1 24 | 2.8% | 2.1% |
现金转化率ICUIPEN
| Q4 25 | — | 1.83× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | 0.32× | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PEN
暂无分部数据
